Related references
Note: Only part of the references are listed.Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China
Yi Zhang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype A POPular Genetics Subanalysis
Daniel M. F. Claassens et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2021)
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy A Meta-Analysis
Naveen L. Pereira et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2021)
Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention
Ziwei Xi et al.
CARDIOVASCULAR DRUGS AND THERAPY (2020)
Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel The ABCD-GENE Score
Dominick J. Angiolillo et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention
Jianan Li et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial
Naveen L. Pereira et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Clopidogrel Pharmacogenetics State-of-the-Art Review and the TAILOR-PCI Study
Naveen L. Pereira et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2019)
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Daniel M. F. Claassens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
Muhammad Shahzeb Khan et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2019)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
Borja Ibanez et al.
EUROPEAN HEART JOURNAL (2018)
Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice Results From the Bern Percutaneous Coronary Intervention Registry
Thomas Zanchin et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2018)
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Larisa H. Cavallari et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2018)
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
Larisa H. Cavallari et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
Joo-Yong Hahn et al.
LANCET (2018)
Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Craig R. Lee et al.
CIRCULATION-GENOMIC AND PRECISION MEDICINE (2018)
Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome
Chor Cheung Tam et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2017)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
Glenn N. Levine et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
Peter C. Austin et al.
STATISTICS IN MEDICINE (2015)
2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Ezra A. Amsterdam et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
East Asian Paradox: Challenge for the Current Antiplatelet Strategy of One-Guideline-Fits-All Races in Acute Coronary Syndrome
Young-Hoon Jeong
CURRENT CARDIOLOGY REPORTS (2014)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Gjin Ndrepepa et al.
CIRCULATION (2012)
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
Jason D. Roberts et al.
LANCET (2012)
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis
Jessica L. Mega et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA Boxed Warning A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
David R. Holmes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Lars Wallentin et al.
LANCET (2010)
Cardiovascular pharmacogenomics and individualized drug therapy
Naveen L. Pereira et al.
NATURE REVIEWS CARDIOLOGY (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Share Paper
